Elevance Health, Inc.
ELV
Positions held
Your positionsELV isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Elevance Health operates in a competitive healthcare plans industry with a strong market position and a recommendation to buy, indicating investor confidence.
- Revenue increased by 1% compared to the prior quarter, reaching $50.5 billion.
- The company's market capitalization stands at approximately $86.8 billion.
- The earnings growth has declined by 13.1%, raising concerns about profitability in the near term.
- Net income for the latest quarter was $1.46 billion, down from $1.76 billion in the previous quarter.
- The trailing P/E ratio is 17.71, which may indicate overvaluation compared to industry peers.
Fundamentals
| Market cap | $86.95B | Enterprise value | $80.62B | Trailing P/E | 17.75 | Forward P/E | 13.55 |
| PEG | 1.32 | Price / book | 1.94 | Beta | 0.71 | Dividend yield | 1.72% |
| Revenue growth | 1.4% | Earnings growth | -13.1% | Gross margin | 26.0% | Operating margin | 4.6% |
| Profit margin | 2.5% | ROE | 11.1% | ROA | 3.8% | Debt / equity | 0.69 |
| Current ratio | 1.52 | Free cash flow | $4.31B | Analyst recommendation | buy | Mean target | $451.48 |
| 52w high | $436.24 | 52w low | $274.84 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $50.5B | $50.2B | $49.7B | $50.7B | $49.8B |
| Op margin | — | — | — | — | — |
| Net income | $1.5B | $1.8B | $547M | $1.2B | $1.7B |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
- Revenue +1% vs prior quarter ($50.5B vs $50.2B).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $199.1B | $176.8B | $171.3B | $156.6B | — |
| Op margin | — | — | — | — | — |
| Net income | $5.7B | $6.0B | $6.0B | $5.9B | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Humana Leads Managed Care Peers in 2027 Medicare Advantage Star Ratings, Deutsche Bank Says
2026-10-09 · Is Clover Health Stock Too Dependent On One Group Of Members?
2026-10-08 · CVS Health Trades at a Discount to Industry: How to Play the Stock?
2026-10-08 · 2 Stocks to Buy Hand Over Fist in October
2026-10-07 · Centene's Operations Improve: Does the 12.34X P/E Make it a Buy?
2026-10-06 · UnitedHealth Q3 Coming Up: Two Questions Investors Can't Ignore
2026-10-06 · Barclays Adjusts Elevance Health Price Target to $469 From $457, Maintains Overweight Rating
2026-10-05 · ELV or DHR: Which Is the Better Value Stock Right Now?
2026-10-05 · Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
2026-10-05 · Evercore ISI Adjusts Elevance Health Price Target to $430 From $440, Maintains In Line Rating
2026-10-02 · Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?
2026-10-02 · How Much Downside Is Left In CVS Health Stock?
Price (daily)
Full chart · RSI · MACD · patternsOn Trade and Ticker